en · de · es · fr · pt
tb-500-notes.peptides3626.com › Blog › Identity And Research Background — Quick Reference

Identity And Research Background — Quick Reference

By Editorial Desk · published 2026-05-09 · last reviewed 2026-06-19 · Blog

The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.

Reviewed 2026-06-19. Anything still debated is marked as such rather than presented as settled.

Identity and Research Background

Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.

TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.

Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.

Thymosin Beta-4 Fragment Background

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Tb-500 at a glance

PropertyValueNotes
Molecular formulaC38H68N10O14Acetylated heptapeptide form
Monoisotopic mass888.5 DaAverage mass about 889 Da
AppearanceWhite to off-white solidUsually supplied as lyophilised powder
Solubility classHighly water solubleAlso dissolves in aqueous buffers
Common synonymsTbeta4 fragment, thymosin beta-4 (17-23)Refer to the same sequence

Identity And Naming Background

Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.

TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.

Related pages on this site

Storage, Handling, and Analytical Checks

Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.

The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.

Handling, Storage, and Analysis

Lyophilised peptide is normally reconstituted with sterile water or a neutral buffer shortly before use. Because repeated freeze-thaw cycles can degrade the material, dividing a reconstituted solution into single-use aliquots is a common practice. Working solutions are usually kept cold and protected from light. The exact shelf life depends on concentration, buffer composition, and handling, so it is often determined empirically rather than assumed.

Peptide bonds are susceptible to hydrolysis under extreme pH and to enzymatic cleavage if proteases are present. Heat, oxidising agents, and prolonged exposure to light also contribute to loss of material. Aggregation can occur at high concentrations or in certain buffer systems, and it may not be visible to the eye. Storage at -20 C or below is typical for both powder and aliquoted solutions, and desiccation of the powder is preferred.

Handling, Storage, and Analytical Verification

Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.

Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.

The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.

Supporting material

These findings suggest that some cocaine-related cognitive deficits are reversible, especially if use begins later in life. A 2018 review found little evidence that chronic cocaine use causes widespread cognitive impairment. Exposure to cocaine may lead to the breakdown of the blood–brain barrier. Cocaine use is frequently associated with involuntary tooth grinding, known as bruxism, which can cause dental attrition and gingivitis. Additionally, stimulants like cocaine, methamphetamine, and even caffeine cause dehydration and dry mouth.

== Coronavirus response == Coronaviruses evade innate immunity during the first ten days of viral infection. In the early stages of infection, SARS-CoV-2 induces an even lower interferon type I (IFN-I) response than SARS-CoV, which itself is a weak IFN-I inducer in human cells. SARS-CoV-2 limits the IFN-III response as well. Reduced numbers of plasmacytoid dendritic cells with age is associated with increased COVID-19 severity, possibly because these cells are substantial interferon producers. Ten percent of patients with life-threatening COVID-19 have autoantibodies against type I interferon. Delayed IFN-I response contributes to the pathogenic inflammation (cytokine storm) seen in later stages of COVID-19 disease. Application of IFN-I prior to (or in the very early stages of) viral infection can be protective, which should be validated in randomized clinical trials. With pegylated IFN lambda, the relative risk for hospitalization with the Omicron strains is reduced by about 80 %.

The clinical significance of hyperlysinemia is the subject of debate in the field with some studies finding no correlation between physical or mental disabilities and hyperlysinemia. In addition to this, mutations in genes related to lysine metabolism have been implicated in several disease states, including pyridoxine-dependent epilepsia (ALDH7A1 gene), α-ketoadipic and α-aminoadipic aciduria (DHTKD1 gene), and glutaric aciduria type 1 (GCDH gene). Hyperlysinuria is marked by high amounts of lysine in the urine. It is often due to a metabolic disease in which a protein involved in the breakdown of lysine is non functional due to a genetic mutation. It may also occur due to a failure of renal tubular transport.

MGM-15, also known as dihydro-7-hydroxy mitragynine, DH-7OH-MIT is an opioid drug which is a semi-synthetic derivative of 7-hydroxymitragynine, a natural product derived from the Southeast Asian tree kratom. MGM-15 was first reported in 2014. It is the 1,2-dihydro derivative of 7-hydroxymitragynine and shows higher potency as an agonist of the μ-opioid receptor and δ-opioid receptor compared to 7-hydroxymitragynine itself. MGM-15 has been sold as a designer drug since early 2025, initially in the US.

Sources: en.wikipedia.org

Notes from published material

Ari and Mac struggle to find time to be together with Mia and Chloe in the Bay. Mac tries to be supportive, but it becomes clear that there are unresolved issues between Ari and Mia. Kipa-Williams told Sarah Ellis of Inside Soap that Ari had no romantic intentions towards Mia, as he is happy with Mac, but then a sense of familiarity creeps in and being with Mia is "second nature" to Ari. Ari later invites Mia to a barbeque at the Parata house, but forgets to tell Mac, who learns about the event from Mia. Mac later sees Ari and Mia sharing a private moment together in the yard. Kipa-Williams said that Mia's presence has stirred up memories of the past that his character thought he had buried. While Samson commented that Mia does not want to get in the way of Ari's relationship and she has "no bad feelings" towards Mac. Ari later ends the relationship because of his unresolved feelings for Mia. Kipa-Williams told TV Week's Stephen Downie "After spending time in prison, Ari has decided to live by a new set of rules and tries to be as honest as possible. He loves Mia and Mac, which is why he needs to break up with Mac and figure out his feelings for Mia and what her being here means to him." In an interview with Susannah Alexander and Daniel Kilkelly of Digital Spy, Kipa-Williams expressed his disappointment about Mac and Ari's break up. He admitted that he was "really sad about it", as he enjoyed the bond he had formed with Weir and wanted their characters to become "a solid couple" similar to Ben Astoni (Rohan Nichol) and Maggie Astoni (Kestie Morassi).

==== Gene and protein expression ==== Approximately 20,000 protein coding genes are expressed in human cells and 75% of these genes are expressed in at least one of the different parts of the digestive organ system. Over 600 of these genes are more specifically expressed in one or more parts of the GI tract and the corresponding proteins have functions related to digestion of food and uptake of nutrients. Examples of specific proteins with such functions are pepsinogen PGC and the lipase LIPF, expressed in chief cells, and gastric ATPase ATP4A and gastric intrinsic factor GIF, expressed in parietal cells of the stomach mucosa. Specific proteins expressed in the stomach and duodenum involved in defence include mucin proteins, such as mucin 6 and intelectin-1.

== Natural occurrences == Synephrine, although already known as a synthetic organic compound, was first isolated as a natural product from the leaves of various Citrus trees, and its presence noted in different Citrus juices, by Stewart and co-workers in the early 1960s. A survey of the distribution of synephrine amongst the higher plants was published in 1970 by Wheaton and Stewart. It has subsequently been detected in Evodia and Zanthoxylum species, all plants of the family Rutaceae. Trace levels (0.003%) of synephrine have also been detected in the dried leaves of Pogostemon cablin (patchouli, Lamiaceae). It is also found in certain cactus species of the genera Coryphantha and Dolichothele. However, this compound is found predominantly in a number of Citrus species, including "bitter" orange varieties.

==== Territorial Grand Orient ==== In the pursuit of an independent and Cuban authority, on May 14, 1821, the Grand Consistory developed the Grande Oriente Territorial Espanol-Americano-Rita Escoces de Francos-masones antiguos y aceptados (English: Territorial Grand Orient of the Spanish-American-Scottish Rite of Ancient and Accepted Freemasons), which was established in Havana. This Grand Orient was then further divided into the Symbolic Grand Orient and the Grand Consistory. Many members of this Grand Orient were officers of the Spanish Army and the Spanish Navy. Their ambitions were evident in the fact that they claimed to hold jurisdiction over Spanish Puerto Rico, New Spain, Mexico, The Floridas, Santo Domingo, and Haiti. On their roster of Lodges, they indeed held authority over a Lodge in Tabasco called Los Amigos Filantropicos (English: Philanthropic Friends).

0. No diabetic foot ulcer is present, but there is a high risk of developing one. 1. A surface ulcer involves full skin thickness but does not yet involve the underlying tissues. 2. A deep ulcer penetrates past the surface, down to the ligaments and muscle. There is no abscess or bone involved yet. 3. A deep ulcer occurs with inflammation of subcutaneous connective tissue or an abscess. This can include infections in the muscle, tendon, joint, and/or bone. 4. The tissue around the area of the ulcer (limited to the toes and forefoot) has begun to decay. This condition is called gangrene. 5. Gangrene has spread from the localized area of the ulcer to become extensive. This involves the whole foot.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.

What amino acids make up this peptide?

It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.

How much human data exists for this sequence?

Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

Network